Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Vitrectomy with daunorubicin].

Krystyna Raczyńska1, Andrzej Gebka, Barbara Iwaszkiewicz-Bilikiewicz

  • 1Katedry i Kliniki Chorób Oczu Akademii Medycznej w Gdańsku.

Klinika Oczna
|January 8, 2005
PubMed
Summary

Daunorubicin, an antimetabolic drug, effectively prevented proliferative vitreoretinopathy (PVR) relapse in retinal detachment surgery patients. This study found no PVR recurrence in eyes treated with intravitreal daunorubicin during vitrectomy over 12 months.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secondary Neovascular Glaucoma in the Course of Diabetes in a Kidney Transplant Recipient: Case Report and Review of the Literature.

Transplantation proceedings·2024
Same author

Microscopic and Biopharmaceutical Evaluation of Emulsion and Self-Emulsifying Oil with Cyclosporine.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

The Level of Cytokines in the Vitreous Body of Severe Proliferative Diabetic Retinopathy Patients Undergoing Posterior Vitrectomy.

Current pharmaceutical design·2018
Same author

Pilot Study of Eyesight Characteristics and Thickness of the Retinal Nerve Fiber and Ganglion Cell-inner Plexiform Layers in Adolescent Patients with Type one Diabetes Mellitus on an Insulin Pump.

Current pharmaceutical design·2018
Same author

The Influence of Silicone Oil on the Ganglion Cell Complex After Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment.

Current pharmaceutical design·2018
Same author

Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2018

Area of Science:

  • Ophthalmology
  • Retinal Surgery
  • Pharmacology

Background:

  • Proliferative vitreoretinopathy (PVR) is a primary cause of retinal surgery failure.
  • Daunorubicin has been investigated for 20 years as a potential antimetabolic treatment for PVR.
  • Rhegmatogenous retinal detachment (RRD) with PVR presents a significant surgical challenge.

Purpose of the Study:

  • To assess the efficacy of intravitreal daunorubicin as an antiproliferative agent in preventing PVR.
  • To evaluate daunorubicin's role in managing eyes with RRD complicated by PVR.
  • To determine if daunorubicin reduces vitreoretinal re-proliferation post-vitrectomy.

Main Methods:

  • Vitrectomy with intraoperative intravitreal daunorubicin infusion (1 microg/ml) in 6 eyes.

Related Experiment Videos

  • Comparison group received vitrectomy with gentamycin infusion (20 mg/ml) in 6 eyes.
  • 12-month follow-up to monitor PVR relapse rates.

    • Main Results:

    • No PVR relapse was observed in the daunorubicin-treated group during the 12-month follow-up.
    • PVR re-proliferation occurred in 2 out of 6 eyes in the control group (gentamycin infusion).
    • Daunorubicin demonstrated a clear reduction in PVR recurrence compared to the control.

    Conclusions:

    • Intravitreal daunorubicin appears to be a beneficial adjuvant therapy for reducing PVR rates.
    • The study suggests daunorubicin's potential to improve outcomes in RRD surgery with PVR.
    • Further investigation into daunorubicin as an antiproliferative agent in retinal detachment is warranted.